INTRODUCTION

Due to the essential role obesity plays in the pathogenesis of metabolic syndrome, a syndrome that is associated with cardiovascular morbidity, considerable interest has arisen in understanding the role obesity plays in cardiovascular disease [1]. Adipose tissue is no longer thought to only store excess energy; rather, it appears to be an active endocrine organ that produces many cytokines, which are known as adipokines [2-6]. These adipokines appear to have systemic effects on the brain, liver, muscles, β-cells, gonads, lymphoid organs, and vasculature [7]. Many studies have examined the role adipose tissue plays in the development of coronary artery disease in patients with metabolic syndrome [8-13], and it is now understood that adipose tissue can cause vascular complications either directly by causing atherosclerosis and inducing inflammatory responses, or indirectly by promoting the development of insulin resistance [14]. These atherosclerosis-inducing pathways are mediated by various adipokines, including adiponectin, leptin, retinol binding protein-4 and resistin [8-12]. Analyses of additional adipokines may help us to further understand the pathogenesis of insulin resistance and its cardiovascular complications.

Chemerin is a recently discovered 16 kDa chemoattractant protein that acts as a ligand for the G-protein receptor CMKLR1 (ChemR23 or DEZ) [15,16]. It is secreted by adipose tissue as prochemerin (18 kDa) [16] and is transformed into an active protein by serine protease cleavage of its C-terminal fragment [17]. In its active form, chemerin regulates the immune system and participates in inflammation by promoting the recruitment of tissue macrophages and plasmacytoid dendritic cells [15,18]. Chemerin is also associated with adipogenesis, as studies with Psammomys obesus have shown that while both chemerin and CMKLR1 are expressed by all tissues, their expression is particularly high in the liver, kidney, and adipose tissue [19]. Moreover, while undifferentiated adipose tissue only expresses low levels of chemerin and CMKLR1, both molecules are expressed at progressively higher levels by differentiated adipocytes [15]. The knockdown of chemerin or CMKLR1 expression in pre-adipocytes severely impairs their differentiation and reduces the expression of genes involved in glucose and lipid metabolism [15]. These observations suggest that chemerin may participate in insulin resistance and its cardiovascular complications.

As mentioned above, chemerin is associated with inflammation, adipogenesis, glucose, and lipid metabolism, all of which may contribute to the development of diabetic cardiovascular complications, especially atherosclerosis [15,18,19]. Therefore, we hypothesized that chemerin levels might be related to other cardiometabolic markers and that an increase in chemerin might reflect the degree of atherosclerotic burden. To further address this question, we examined whether the chemerin levels in Korean patients with coronary artery disease correlate with specific cardiometabolic parameters.

METHODS

Subjects

Of the patients who underwent coronary angiography at Keimyung University Dongsan Hospital, Daegu, Korea from November 2006 to April 2007, 131 were proven by coronary angiography to have meaningful stenosis (≥50%) and were recruited. Patients who did not have infections or renal or liver failure were eligible for the study. The medical history of each patient was determined by a questionnaire. The present study was approved by the local Ethical Review Committee of the Keimyung University School of Medicine. All participants gave informed consent.

Anthropometric, blood pressure, and biochemical measurements

All patients provided their personal information, and their height, weight, and waist circumference were measured. Body mass index (BMI) was calculated (kg/m²). Blood pressure was measured by an electronic device (FA-94H; Fanics, Korea) after sitting for 5 minutes. Blood was drawn in the morning after a 12-hour fast. The fasting serum glucose levels were measured by using the glucose oxidase method (Cobas Integra 800; Roche, Basel, Switzerland). Fasting serum insulin concentrations were measured by a radioimmunoassay kit (Insulin Myria; TechnoGenetics, Milano, Italy). The homeostasis model of assessment of insulin resistance (HOMA-IR) was calculated as fasting insulin×(fasting glucose/22.5). The levels of the following biochemical markers were measured by enzymatic methods (Cobas Integra 800): serum triglyceride, total cholesterol, and high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol. High sensitive C-reactive protein (hsCRP) concentrations were measured using the latex method (TBA-200FR; Tosiba, Tokyo, Japan). Serum homocysteine concentrations were measured using an Axsym (Abbott, Abbott Park, IL, USA). The separated sera were stored at -70℃ until the chemerin levels could be measured using a commercially available ELISA (R&D, Minneapolis, MN, USA) as previously described [19]. The capture antibody and detection antibody were used. Intra- and inter-assay coefficients of variance for the chemerin ELISA were 5.0% and 10.0%, respectively. The sensitivity of the ELISA assay was 1 to 10 ng/dL, and the midrange of the assay was 5 ng/dL. This kit can detect human chemerin concentration by 0.5 ng/dL at least.

Coronary angiogram

Angiographic images were reviewed by an experienced cardiologist who was unaware of the patient's biochemistry results. As outlined in the Duke coronary artery index [20,21], we defined significant stenosis as >50% of the lumen diameter. The degree of stenosis of the diseased vessels served as a severity index. Patients were divided into two groups; those with one stenotic vessel (n=68) and those with multiple stenotic vessels, including left main disease (n=63).

Statistical analysis

The data are expressed as mean±standard deviation. We performed Student's t-test to compare chemerin levels and other metabolic factors in patients divided according to the number of stenotic vessels, and checked multiple binary logistic regression analysis (95% confidence interval) on risk of multiple vessel stenosis. We performed Pearson's correlation analyses between chemerin and cardiometabolic factors using SPSS version 12.0 software for Windows (SPSS Inc., Chicago, IL, USA). P values of less than 0.05 were considered statistically significant.

RESULTS

Clinical and metabolic subject characteristics

Table 1 shows the clinical characteristics of the 131 study subjects, of whom 86 (65.6%) and 45 (33.6%) were men and women, respectively. In total, 69 (52.7%) patients were smokers, 32 (24.4%) had diabetes and 85 (64.9%) had hypertension. Mean BMI was 24.1±2.8 kg/m². Thirty-five (26.7%) patients were overweight (BMI 23 to 24.9 kg/m²) and 51 (39.0%) patients were obese (BMI >25 kg/m²). Angiography showed that 68 (49.8%) patients had one vessel disease, 39 (32.2%) had two vessel disease, 16 (12.3%) had triple vessel disease, and 8 (5.8%) had left main disease. In addition, 84 (64.1%) patients were being treated with anti-platelet agents, 32 (24.4%) patients were being treated with an oral hypoglycemic agent, 85 (64.9%) patients were being treated with an antihypertensive drug, and 48 (36.7%) patients were being treated with statins before enrollment.

Correlation between serum chemerin concentrations and cardiometabolic parameters

There were significant but weak correlations between serum chemerin concentrations and fasting glucose, triglyceride, total cholesterol, LDL-cholesterol and hsCRP (Table 2). However, serum chemerin concentrations did not correlate significantly with fasting insulin, HDL-cholesterol or homocysteine levels, BMI, waist circumference, HOMA-IR and systolic and diastolic blood pressure.

Correlation between serum chemerin concentrations and coronary angiographic findings

To determine whether serum chemerin concentration is associated with coronary artery disease, we analyzed the correlation between serum chemerin concentrations and coronary stenosis (%) in all participants. Fig. 1 shows how serum chemerin concentrations correlate with the degree of coronary artery stenosis. We measured a significant positive correlation, albeit weak, between these two parameters (r=0.0200, P=0.022). Moreover, the group with multiple vessel disease, including left main disease, showed higher age and chemerin, LDL, and CRP levels than the one vessel disease group (Table 3). However, Table 4 depicts that chemerin level is not an independent risk factor in multiple vessel disease.

DISCUSSION

Accumulating evidence has suggested that adipokines play an important role in the development of coronary artery disease in patients with metabolic syndrome [8-13]. Recent studies have shown that chemerin levels associate significantly with metabolic components of the metabolic syndrome [19,22,23]. However, whether chemerin levels are also associated with cardiovascular parameters in patients with coronary artery disease remains to be elucidated. In this study, we investigated whether circulating chemerin concentrations correlate with the cardiometabolic parameters of Korean patients with coronary artery disease. We observed that serum chemerin concentrations were positively correlated with fasting glucose, triglyceride, total cholesterol, LDL-cholesterol, and hsCRP. Serum chemerin concentrations also had a significant correlation with the degree of coronary artery stenosis, although we recognize this association was weak.

Chemerin is a recently identified chemoattractant protein that induces leukocyte migration; in addition, its receptor is expressed by tissue macrophages [16-18]. These observations suggest that chemerin functions in the development of inflammatory diseases, including atherosclerosis. In this study, we found that chemerin levels correlated positively with hsCRP levels. hsCRP is a circulating marker of inflammation that is predominantly produced by the liver in response to IL-6 [24]. Patients with metabolic syndrome have higher CRP levels than healthy individuals, and this high CRP level is an independent risk factor for type 2 diabetes and cardiovascular disease [24-26]. CRP also directly promotes the inflammatory component of atherosclerosis by inducing adhesion molecule expression by human endothelial cells [27]. Recently, Lehrke et al. [22] analyzed the relationship between chemerin and metabolic components in patients with chest pain. In their study, chemerin is associated with coronary plaque burden and the number of non-calcified plaques, but these correlations dropped out after adjusting for other cardiovascular risk factors. In contrast to their study, this report shows that there was a significant but weak correlation between chemerin concentrations and the degree of coronary artery stenosis even after adjusting for other factors. Moreover, the group with multiple vessel disease had higher chemerin levels than the group with one vessel disease. Thus, our study suggests the possibility that chemerin could be associated with coronary artery disease; however our study did not show that chemerin level was not an independent risk factor in multiple vessel disease.

In addition to having pro-inflammatory effects, chemerin is a novel adipokine that has been associated with metabolic syndrome phenotypes [22]. Chemerin has been shown to regulate adipocyte differentiation and the expression of adipocyte genes involved in glucose and lipid homeostasis [19]. While Bozaoglu et al. [19] previously failed to detect a significant difference in the chemerin levels of subjects with normal glucose tolerance and subjects with type 2 diabetes, obese subjects were found to have significantly higher chemerin levels than lean subjects. Moreover, the chemerin levels in normal glucose-tolerant subjects were found to correlate significantly with various metabolic parameters, including BMI, waist circumference, waist-hip ratio, fasting glucose levels, fasting insulin levels, plasma triglyceride levels, and blood pressure [19]. However, this study shows that while serum chemerin concentrations significantly but weakly correlated with fasting glucose, triglyceride, total cholesterol and LDL cholesterol levels, they did not correlate with fasting insulin levels, HOMA-IR, BMI, waist circumference or blood pressure. This discrepancy may be due to differences between the study populations of the previous study and our own. In particular, our study included subjects who were taking antihypertensives, oral hypoglycemia agents and statins.

This study has certain limitations that we will address here. First, we measured the number of significant coronary stenoses without individualizing each coronary stenosis according to the type of lesion involved. If we had done so, we could have obtained a more accurate correlation between chemerin and coronary stenosis (%). Second, we enrolled patients with significant coronary artery stenosis (mentioned in Methods; >50% of patients) without enrolling healthy controls with no coronary artery disease. Thus, we could not determine the odds ratio of various cardiometabolic factors in coronary atherosclerosis. Third, the chemerin ELISA kit used in this study measures full-length chemerin form. Chemerin protein exists as a full-length protein in plasma, but this form of the protein is known to have lower bioactivity than prochemerin [28]. However, despite these shortcomings, the results suggest that chemerin could be useful as a predictor of metabolic syndrome and cardiovascular complications.

In conclusion, we found that circulating chemerin concentrations weakly but significantly correlated with several cardiometabolic parameters as well as the severity of coronary artery stenosis in Korean patients with coronary artery disease. However, multivariate analysis showed chemerin was not an independent risk factor for multiple vessel disease. Additional investigations are necessary to fully elucidate the role chemerin plays in the development and/or progression of cardiovascular disease.

Acknowledgements

ACKNOWLEDGMENTS

This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A08-4335-AA2004-08N1-00020B).

NOTES

No potential conflict of interest relevant to this article was reported.

REFERENCES

• 1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977. ArticlePubMed
• 2. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537-1545. PubMed
• 3. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-355. ArticlePubMed
• 4. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12. PubMed
• 5. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34:2-11. ArticlePubMed
• 6. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-332. ArticlePubMed
• 7. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-481. ArticlePubMedPMC
• 8. Steffens S, Mach F. Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ Res 2008;102:140-142. PubMed
• 9. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004;90:528-533. ArticlePubMedPMC
• 10. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001;88:954-960. PubMed
• 11. Ingelsson E, Sundstrom J, Melhus H, Michaelsson K, Berne C, Vasan RS, Riserus U, Blomhoff R, Lind L, Arnlov J. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis 2009;206:239-244. ArticlePubMed
• 12. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, Windler E. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005;13:1764-1771. ArticlePubMed
• 13. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288:H2031-H2041. ArticlePubMed
• 14. Kowalska I. Role of adipose tissue in the development of vascular complications in type 2 diabetes mellitus. Diabetes Res Clin Pract 2007;78(Suppl 1):S14-S22.Article
• 15. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-28188. ArticlePubMed
• 16. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brezillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-985. ArticlePubMedPMCPDF
• 17. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, Butcher EC. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005;280:34661-34666. ArticlePubMed
• 18. Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol 2005;174:244-251. ArticlePubMedPDF
• 19. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-4694. ArticlePubMedPDF
• 20. Mark DB, Nelson CI, Califf RM, Harrell FE Jr, Lee KL, Jones RH, Fortin DF, Stack RS, Glower DD, Smith LR, DeLong ER, Smith PD, Reves JG, Jollis JG, Tcheng JE, Muhlbaier LH, Lowe JE, Phillips HR, Pryor DB. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994;89:2015-2025. ArticlePubMed
• 21. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox C, Brinker J, Lima JA. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008;359:2324-2336. ArticlePubMed
• 22. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Goke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009;161:339-344. ArticlePubMed
• 23. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D, Lewandowski KC, O'Hare JP, Lehnert H, Randeva HS. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009;58:1971-1977. ArticlePubMedPMCPDF
• 24. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812. ArticlePubMedPMC
• 25. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369. ArticlePubMed
• 26. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843. ArticlePubMed
• 27. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168. ArticlePubMed
• 28. Yoshimura T, Oppenheim JJ. Chemerin reveals its chimeric nature. J Exp Med 2008;205:2187-2190. ArticlePubMedPMCPDF

Fig. 1

Correlation between chemerin levels and the degree of coronary artery stenosis. Pearson's correlation coefficient=0.21; P<0.022.

Table 1

Clinical and metabolic characteristics of subjects

Data are presented as mean±standard deviation or number (%).

BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; HOMA-IR, homeostasis model of assessment of insulin resistance; hsCRP, high sensitive C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; Stenosis (%), percentage of coronary artery stenosis.

Table 2

Correlation between chemerin and cardiometabolic parameters

The P values are from Pearson's correlations.

BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; HOMA-IR, homeostasis model of assessment of insulin resistance; hsCRP, high sensitive C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 3

Characteristics in patients divided according to the number of stenotic vessels and presence of left main lesions

Data are presented as mean±standard deviation.

Patients were divided according to one stenotic vessel (one vessel disease) or multiple stenotic vessels (multiple vessel disease).

The P values are from Student's t-test.

BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; HOMA, homeostasis model of assessment; hsCRP, high sensitive C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure.

^aMultiple vessel disease included two and triple vessel disease and left main disease.

Table 4

Multiple binary logistic regression on risk of multiple vessel stenosis

OR, odds ratio; CI, confidence interval; LDL, low density lipoprotein; CRP, C-reactive protein.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Adipokine chemerin overexpression in trophoblasts leads to dyslipidemia in pregnant mice: implications for preeclampsia
  Lunbo Tan, Zijun Ouyang, Zhilong Chen, Fen Sun, Haichun Guo, Feng Wang, Monique Mulder, Yuan Sun, Xifeng Lu, Jian V. Zhang, A. H. Jan Danser, Koen Verdonk, Xiujun Fan, Qing Yang
  Lipids in Health and Disease.2023;[Epub]     CrossRef
• Chemerin Levels in Acute Coronary Syndrome: Systematic Review and Meta-Analysis
  Abdulrahman Ismaiel, Mohammad Zeeshan Ashfaq, Daniel-Corneliu Leucuta, Mohamed Ismaiel, Dilara Ensar Ismaiel, Stefan-Lucian Popa, Dan L Dumitrascu
  Laboratory Medicine.2022; 53(6): 552.     CrossRef
• Prognostic value of plasma adipokine chemerin in patients with coronary artery disease
  Bo Wang, Wenxin Kou, Shuya Ji, Rongrong Shen, Hongwei Ji, Jianhui Zhuang, Yifan Zhao, Bo Li, Wenhui Peng, Xuejing Yu, Hailing Li, Yawei Xu
  Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
• Role of Chemerin in Cardiovascular Diseases
  Mirjana T. Macvanin, Manfredi Rizzo, Jelena Radovanovic, Alper Sonmez, Francesco Paneni, Esma R. Isenovic
  Biomedicines.2022; 10(11): 2970.     CrossRef
• Chemerin in inflammatory diseases
  Xin Su, Ye Cheng, Guoming Zhang, Bin Wang
  Clinica Chimica Acta.2021; 517: 41.     CrossRef
• Chemerin activity in selected pathological states of human body – A systematic review
  Magdalena Acewicz, Irena Kasacka
  Advances in Medical Sciences.2021; 66(2): 270.     CrossRef
• Chemerin in atherosclerosis
  Jia-Xiang Sun, Chi Zhang, Zhe-Bin Cheng, Mu-Yao Tang, Yi-Zhang Liu, Jie-Feng Jiang, Xuan Xiao, Liang Huang
  Clinica Chimica Acta.2021; 520: 8.     CrossRef
• Serum Chemerin Concentration Is Associated with Proinflammatory Status in Chronic Coronary Syndrome
  Anna Szpakowicz, Malgorzata Szpakowicz, Magda Lapinska, Marlena Paniczko, Slawomir Lawicki, Andrzej Raczkowski, Marcin Kondraciuk, Emilia Sawicka, Malgorzata Chlabicz, Marcin Kozuch, Maciej Poludniewski, Slawomir Dobrzycki, Irina Kowalska, Karol Kaminski
  Biomolecules.2021; 11(8): 1149.     CrossRef
• Novo Efeito Cardioprotetor da L-Carnitina em Camundongos Obesos Diabéticos: Regulação da Expressão de Quemerina e CMKLRI no Coração e Tecidos Adiposos
  Rezvan Amiri, Mohammad Reza Tabandeh, Seyed Ahmad Hosseini
  Arquivos Brasileiros de Cardiologia.2021; 117(4): 715.     CrossRef
• The role of adipokines in the regulation of cardiovascular function
  A. V. Karpushev, V. B. Mikhailova
  "Arterial’naya Gipertenziya" ("Arterial Hypertension").2020; 25(5): 448.     CrossRef
• The associations among RARRES2 rs17173608 gene polymorphism, serum chemerin, and non-traditional lipid profile in patients with metabolic syndrome
  Marwa A. Dahpy, Marwa K. Khairallah, Nashwa Mostafa A. Azoz, Ghada M. Ezzat
  Egyptian Journal of Medical Human Genetics.2020;[Epub]     CrossRef
• Serum chemerin as a predictor of left ventricle hypertrophy in patients with coronary artery disease
  NohaHasssanin Hanboly, Yasser Sharaf, Mervat Al-Anany, Essam Saeed
  Nigerian Journal of Cardiology.2019; 16(1): 25.     CrossRef
• Association of Circulating Chemerin With Subclinical Parameters of Atherosclerosis
  Stephanie Zylla, Marcus Dörr, Henry Völzke, Ulf Schminke, Stephan B. Felix, Matthias Nauck, Nele Friedrich
  Arteriosclerosis, Thrombosis, and Vascular Biology.2018; 38(7): 1656.     CrossRef
• Six weeks of combined aerobic and resistance exercise using outdoor exercise machines improves fitness, insulin resistance, and chemerin in the Korean elderly: A pilot randomized controlled trial
  Dong-Il Kim, Dong Hoon Lee, Sunghyun Hong, Sung-won Jo, Young-shin Won, Justin Y. Jeon
  Archives of Gerontology and Geriatrics.2018; 75: 59.     CrossRef
• Relationship between serum chemerin levels and insulin resistance index and cardio–respiratory function in non–active obese and lean men
  Mehdi Abbaszadegan, Farhad Kouhi achachluie
  Advances in Obesity, Weight Management & Control.2018;[Epub]     CrossRef
• Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis
  Tarek M.K. Motawi, Soliman G. Mahdy, Maha M. El-Sawalhi, Eman N. Ali, Rania Farag A. El-Telbany
  Canadian Journal of Physiology and Pharmacology.2018; 96(1): 38.     CrossRef
• Plasma CXCL1 levels and TRAF3IP2 variants in patients with myocardial infarction
  Safoora Pordel, Mahdi Sajedi Khanian, Mohammad Hossein Karimi, Hossein Nikoo, Mehrnoosh Doroudchi
  Journal of Clinical Laboratory Analysis.2018;[Epub]     CrossRef
• Serum Chemerin Levels are Associated with Visceral Adiposity, Independent of Waist Circumference, in Newly Diagnosed Type 2 Diabetic Subjects
  Dae Young Cheon, Jun Goo Kang, Seong Jin Lee, Sung Hee Ihm, Eun Jig Lee, Moon Gi Choi, Hyung Joon Yoo, Chul Sik Kim
  Yonsei Medical Journal.2017; 58(2): 319.     CrossRef
• The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents
  Zahra Maghsoudi, Roya Kelishadi, Mohammad Javad Hosseinzadeh-Attar
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2016; 10(2): S43.     CrossRef
• Chemerin processing in the myocardium: A mechanism in search of a function
  Michael V.G. Latronico, Gianluigi Condorelli
  Journal of Molecular and Cellular Cardiology.2016; 100: 21.     CrossRef
• Chemerin as an independent predictor of cardiovascular event risk
  Sinan İnci, Gökhan Aksan, Pınar Doğan
  Therapeutic Advances in Endocrinology and Metabolism.2016; 7(2): 57.     CrossRef
• Chemerin level in pregnancies complicated by preeclampsia and its relation with disease severity and neonatal outcomes
  Orkun Cetin, Zehra Kurdoglu, Mertihan Kurdoglu, H. Guler Sahin
  Journal of Obstetrics and Gynaecology.2016; : 1.     CrossRef
• Chemerin in renal dysfunction and cardiovascular disease
  Mario Bonomini, Assunta Pandolfi
  Vascular Pharmacology.2016; 77: 28.     CrossRef
• High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events — Insights from phenotype and genotype characterization
  Andreas Leiherer, Axel Muendlein, Elena Kinz, Alexander Vonbank, Philipp Rein, Peter Fraunberger, Cornelia Malin, Christoph H. Saely, Heinz Drexel
  Vascular Pharmacology.2016; 77: 60.     CrossRef
• Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia
  Liqiong Wang, Tianli Yang, Yiling Ding, Yan Zhong, Ling Yu, Mei Peng
  Endocrine.2015; 48(1): 299.     CrossRef
• Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation
  Erkan Özcan, N. Işıl Saygun, Muhittin A. Serdar, Nezahat Kurt
  Clinical Oral Investigations.2015; 19(4): 921.     CrossRef
• Elevated serum chemerin in Chinese women with hyperandrogenic PCOS
  LiQiong Wang, Yan Zhong, YiLing Ding, XiaoBo Shi, Jian Huang, FuFan Zhu
  Gynecological Endocrinology.2014; 30(10): 746.     CrossRef
• Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity?
  Karla Bianca Neves, Núbia S. Lobato, Rhéure Alves Moreira Lopes, Fernando P. Filgueira, Camila Ziliotto Zanotto, Ana Maria Oliveira, Rita C. Tostes
  Clinical Science.2014; 127(2): 111.     CrossRef
• Chemerin levels as predictor of acute coronary events: A case–control study nested within the veterans affairs normative aging study
  Konstantinos N. Aronis, Ayse Sahin-Efe, John P. Chamberland, Avron Spiro, Pantel Vokonas, Christos S. Mantzoros
  Metabolism.2014; 63(6): 760.     CrossRef
• The predictive value of the first-trimester maternal serum chemerin level for pre-eclampsia
  Qiu-Lian Xu, Min Zhu, Yan Jin, Nan Wang, Hai-Xia Xu, Li-Mei Quan, Shan-Shan Wang, Shan-Shan Li
  Peptides.2014; 62: 150.     CrossRef
• Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography
  Chi-Sheng Hung, Yen-Wen Wu, Jei-Yie Huang, Pei-Ying Hsu, Ming-Fong Chen, Xin-Liang Ma
  PLoS ONE.2014; 9(5): e97710.     CrossRef
• Towards an integrative approach to understanding the role of chemerin in human health and disease
  J. L. Rourke, H. J. Dranse, C. J. Sinal
  Obesity Reviews.2013; 14(3): 245.     CrossRef
• The association between chemerin and homeostasis assessment of insulin resistance at baseline and after weight reduction via lifestyle modifications in young obese adults
  Mi Kyung Lee, Sang Hui Chu, Duk Chul Lee, Ki Yong An, Ji-Hye Park, Dong Il Kim, Jiyoung Kim, Sunghyun Hong, Jee Aee Im, Ji Won Lee, Justin Y. Jeon
  Clinica Chimica Acta.2013; 421: 109.     CrossRef
• Elevated Chemerin Levels in Pakistani Men: An Interrelation with Metabolic Syndrome Phenotypes
  Syeda Sadia Fatima, Kiymet Bozaoglu, Rehana Rehman, Faiza Alam, Abdul Shakoor Memon, Pascale Chavatte-Palmer
  PLoS ONE.2013; 8(2): e57113.     CrossRef
• Chemerin: a potential endocrine link between obesity and type 2 diabetes
  Alexandra A. Roman, Sebastian D. Parlee, Christopher J. Sinal
  Endocrine.2012; 42(2): 243.     CrossRef
• Elastase and Tryptase Govern TNFα-Mediated Production of Active Chemerin by Adipocytes
  Sebastian D. Parlee, Jenna O. McNeil, Shanmugam Muruganandan, Christopher J. Sinal, Kerry B. Goralski, Charaf Benarafa
  PLoS ONE.2012; 7(12): e51072.     CrossRef
• Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus
  Hyun Min Kim, Byung-Wan Lee, Young-Mi Song, Won Jin Kim, Hyuk-Jae Chang, Dong-Hoon Choi, Hee Tae Yu, EunSeok Kang, Bong Soo Cha, Hyun Chul Lee
  Cardiovascular Diabetology.2012;[Epub]     CrossRef
• The association of serum chemerin level with risk of coronary artery disease in Chinese adults
  Qun Yan, Yifei Zhang, Jie Hong, Weiqiong Gu, Meng Dai, Juan Shi, Ying Zhai, Weiqing Wang, Xiaoying Li, Guang Ning
  Endocrine.2012; 41(2): 281.     CrossRef
• Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea
  Jung Hee Kim, Dae Jung Kim, Hak Chul Jang, Sung Hee Choi
  Diabetes & Metabolism Journal.2011; 35(6): 571.     CrossRef
• Chemerin: A Novel Link between Inflammation and Atherosclerosis?
  Eun-Jung Rhee
  Diabetes & Metabolism Journal.2011; 35(3): 216.     CrossRef

About this article

Hah YJ, Kim NK, Kim MK, Kim HS, Hur SH, Yoon HJ, Kim YN, Park KG. Relationship between Chemerin Levels and Cardiometabolic Parameters and Degree of Coronary Stenosis in Korean Patients with Coronary Artery Disease. Diabetes Metab J. 2011;35(3):248-254.

Received: May 31, 2010; Accepted: Dec 14, 2010

DOI: https://doi.org/10.4093/dmj.2011.35.3.248.

Download citation ↓